Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062060 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
A Phase 3 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 325
- Enrollment target
NCT02062060: Completed Phase 3 study, sponsored by Dr. Reddy's Laboratories Limited.
NCT02062060 is a Phase 3 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 325 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02062060, a Phase 3 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 325 participants
- Enrollment target
Study Summary
Purpose of this study is to evaluate the efficacy of at-home administration of a single application of abametapir lotion 0.74% w/w for the treatment of head lice.
Primary Outcome
The outcome is measured by lice evaluations performed by trained lice evaluator from baseline through follow up visits.
Interventions
- DRUG Vehicle Lotion
- DRUG Abametapir Lotion 0.74% w/w
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
What the finished NCT02062060 record still lists
NCT02062060 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Lotion is the first listed.
NCT02062060 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02062060 about?
NCT02062060 is a clinical study titled "Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation". Purpose of this study is to evaluate the efficacy of at-home administration of a single application of abametapir lotion 0.74% w/w for the treatment of head lice.
What is the current status of trial NCT02062060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 325 participants. The study started on 2014-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02062060?
The interventions under investigation include: Vehicle Lotion (DRUG), Abametapir Lotion 0.74% w/w (DRUG).
Who is sponsoring clinical trial NCT02062060?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02062060's enrollment target sits among peer trials
325 1076th of 2000 higher than 922 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia